Cannabidiol gel ZYN002 for fragile X fails to meet goal in clinical trial
A large clinical trial investigating the effects of Harmony Biosciences’ cannabidiol (CBD) gel ZYN002 on behavioral symptoms in children and young adults with fragile X syndrome has failed to meet its primary goal, the developer announced. Data from the Phase 3 trial, called RECONNECT (NCT04977986), showed no…